Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Treilleux

Showing results (121-130 of 186) with videos related to

Pageof 19
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 12, 2023
The KAT6B::KANSL1 Fusion Defines a New Uterine Sarcoma With Hybrid Endometrial Stromal Tumor and Smooth Muscle Tumor FeaturesAlexis Trecourt, Rihab Azmani, Isabelle Hostein, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2021
A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)Mario Campone, Thomas Bachelot, Isabelle Treilleux, et al.
Scientific Reports|April 29, 2020
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypesSolene De Talhouet, Julien Peron, Aurelie Vuilleumier, et al.
Science Immunology|April 19, 2020
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancerMargaux Hubert, Elisa Gobbini, Coline Couillault, et al.
Cancer Research|June 24, 2011
Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancerSana Intidhar Labidi-Galy, Vanja Sisirak, Pierre Meeus, et al.
Bulletin Du Cancer|September 10, 2025
[Understanding biology to identify new therapeutic targets beyond chemotherapy in ovarian granulosa cell tumors]Sil Endale Ahanda, Alexandra Lainé, Brunhilde Hanvic, et al.
Plos Genetics|June 2, 2012
EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic miceAnne-Pierre Morel, George W Hinkal, Clémence Thomas, et al.
Bulletin Du Cancer|March 3, 2020
Detailed overview on rare malignant ovarian tumorsStefanie Aust, Lauriane Eberst, Olivier Tredan, et al.
British Journal of Cancer|January 5, 2024
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestaneHélène Vanacker, Isabelle Treilleux, Camille Schiffler, et al.
Cancer Research|February 27, 2009
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcomeMichael Gobert, Isabelle Treilleux, Nathalie Bendriss-Vermare, et al.
Pageof 19

Showing results (121-130 of 186) with videos related to

Sort By:
Pageof 19
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 12, 2023
The KAT6B::KANSL1 Fusion Defines a New Uterine Sarcoma With Hybrid Endometrial Stromal Tumor and Smooth Muscle Tumor FeaturesAlexis Trecourt, Rihab Azmani, Isabelle Hostein, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2021
A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)Mario Campone, Thomas Bachelot, Isabelle Treilleux, et al.
Scientific Reports|April 29, 2020
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypesSolene De Talhouet, Julien Peron, Aurelie Vuilleumier, et al.
Science Immunology|April 19, 2020
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancerMargaux Hubert, Elisa Gobbini, Coline Couillault, et al.
Cancer Research|June 24, 2011
Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancerSana Intidhar Labidi-Galy, Vanja Sisirak, Pierre Meeus, et al.
Bulletin Du Cancer|September 10, 2025
[Understanding biology to identify new therapeutic targets beyond chemotherapy in ovarian granulosa cell tumors]Sil Endale Ahanda, Alexandra Lainé, Brunhilde Hanvic, et al.
Plos Genetics|June 2, 2012
EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic miceAnne-Pierre Morel, George W Hinkal, Clémence Thomas, et al.
Bulletin Du Cancer|March 3, 2020
Detailed overview on rare malignant ovarian tumorsStefanie Aust, Lauriane Eberst, Olivier Tredan, et al.
British Journal of Cancer|January 5, 2024
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestaneHélène Vanacker, Isabelle Treilleux, Camille Schiffler, et al.
Cancer Research|February 27, 2009
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcomeMichael Gobert, Isabelle Treilleux, Nathalie Bendriss-Vermare, et al.
Pageof 19